RECRUITING

A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)

Description

This study will enroll adult participants with early-stage (stage II-IIIB) non-small cell lung cancer for whom surgery is planned. The aim is to find out whether an investigational treatment (consisting of the immunotherapy drug cemiplimab plus chemotherapy plus a third drug) works better than cemiplimab plus chemotherapy without the additional drug. The study is also looking at several other research questions, including: * What are the side effects associated with the investigational treatments in comparison to the control treatment? * Do the investigational treatments or the control treatment have an effect on the type of surgery that is performed? * How much of the study drug(s) are in the blood at a given time? * Does the body make antibodies against the study drug(s) (which could make the drug(s) less effective or could lead to side effects)?

Conditions

Non-Small Cell Lung Cancer
Talk to us

Related Conditions:

Non-Small Cell Lung Cancer

Study Overview

On this page

Study Details

Study overview

This study will enroll adult participants with early-stage (stage II-IIIB) non-small cell lung cancer for whom surgery is planned. The aim is to find out whether an investigational treatment (consisting of the immunotherapy drug cemiplimab plus chemotherapy plus a third drug) works better than cemiplimab plus chemotherapy without the additional drug. The study is also looking at several other research questions, including: * What are the side effects associated with the investigational treatments in comparison to the control treatment? * Do the investigational treatments or the control treatment have an effect on the type of surgery that is performed? * How much of the study drug(s) are in the blood at a given time? * Does the body make antibodies against the study drug(s) (which could make the drug(s) less effective or could lead to side effects)?

A Randomized Phase 2 Platform Study to Evaluate Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for the Perioperative Treatment of Patients With Resectable Non-Small Cell Lung Cancer

A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)

Condition
Non-Small Cell Lung Cancer
Intervention / Treatment

-

Contacts and Locations

Orange

University of California Irvine, Orange, California, United States, 92868

Skokie

Orchard Healthcare Research Inc., Skokie, Illinois, United States, 60077

Watertown

Prairie Lakes Healthcare System, Watertown, Massachusetts, United States, 57201

Detroit

Karmanos Cancer Institute, Detroit, Michigan, United States, 48201

Farmington Hills

Detroit Clinical Research Center, Farmington Hills, Michigan, United States, 48334

Morristown

Morristown Medical Center, Morristown, New Jersey, United States, 07960

New Brunswick

Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States, 08901

Portland

Providence Portland Medical Center, Portland, Oregon, United States, 97213

Providence

Lifespan Cancer Institute, Providence, Rhode Island, United States, 02903

Knoxville

University of Tennessee Medical Center, Knoxville, Tennessee, United States, 37920

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Histologically confirmed stage II through IIIB (N2) NSCLC, that is considered resectable with curative intent, as described in the protocol
  • 2. Measurable disease per Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.1
  • 3. Available formalin-fixed paraffin-embedded (FFPE) tumor sample blocks for submission, as described in the protocol
  • 4. Eastern Cooperative Oncology Group Performance Status scale (ECOG PS) of 0 to 1
  • 5. Adequate organ and bone marrow function, as described in the protocol
  • 1. Any systemic anti-cancer therapy or radiotherapy for the current tumor, as described in the protocol
  • 2. Presence of known oncogenic alterations in epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) in the tumor prior to randomization, as described in the protocol
  • 3. Presence of grade≥ 2 peripheral neuropathy
  • 4. Another malignancy that is progressing or requires active treatment, as described in the protocol

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Regeneron Pharmaceuticals,

Clinical Trial Management, STUDY_DIRECTOR, Regeneron Pharmaceuticals

Study Record Dates

2030-05-02